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Treatment of generalized anxiety disorder
Anxiety disorders—generalized anxiety disorder (GAD), obsessive-compulsive dis-
order (OCD), panic disorder (PD), post-traumatic stress disorder (PTSD), and social 
anxiety disorder (SAD)—are common, persistent, and cause substantial impairment. 
With lifetime prevalence estimates of over 25%, they constitute a group that is the 
most frequently occurring of psychiatric disorders (Kessler et al 1994). They are also 
expensive, with the annual cost of anxiety disorders in the US estimated to be US$42.3 
billion in 1990 and US$65 billion in 1994 (Greenberg et al 1999), representing a sub-
stantial burden in the direct costs of medication and psychotherapy as well as indirect 
costs associated with impaired functioning in social, educational, and employment 
aspects of life. Traditionally, anxiety disorders were treated with benzodiazepines, and 
despite the shortcomings of these agents in terms of long-term use and habituation, they 
are still widely prescribed, especially diazepam and lorazepam. Newer variations like 
clonazepam and alprazolam have also found their place. The 5-HT1A partial agonist 
buspirone has proven efﬁ  cacy in anxiety disorders, as do some psychological treat-
ments, especially cognitive behavior therapy (CBT). However, treatment of all anxiety 
disorders has largely been taken over by the selective serotonin reuptake inhibitors 
(SSRI) group of antidepressants to the extent that the anxiety disorders have become 
known as the ‘serotonergic disorders’ (Aouizerate et al 2005). Indeed many national 
guidelines for the management of anxiety disorders recommend the use of SSRIs as 
ﬁ  rst-line treatment (Baldwin et al 2005; CADTGI 2007). 
Neuropsychiatric Disease and Treatment has previously published several articles 
on anxiety disorders, including adult (Aouizerate et al 2005) and pediatric OCD (Lewin 
et al 2006) as well as a review of the use of one SSRI, ﬂ  uvoxamine, in the treatment of 
anxiety disorders particularly OCD (Irons 2005). Efﬁ  cacy in anxiety disorders is not 
conﬁ  ned to SSRIs, however, and most antidepressants, particularly but not exclusively 
those with a serotonergic arm to their pharmacology, are in fact anxiolytic – in the 
previous issue of the journal, the efﬁ  cacy of the SNRI venlafaxine in panic disorder 
was reviewed (Katzman and Jacobs 2007). In this issue the focus is on the treatment 
of generalized anxiety disorder (GAD). 
Generalized anxiety disorder is among the most common of mental disorders in 
primary care, with a reported 12-month and lifetime prevalence in Europe of 1.5% 
and 5.1%, respectively (Lieb et al 2005). It is characterized by excessive and inap-
propriate worrying that persists for 6 months or more and is not restricted to particular 
circumstances. Six key symptoms include restlessness, fatigue, difﬁ  culty concentrating, 
irritability, muscle tension, and disturbed sleep, 3 of which must be present for the 
diagnosis (APA 2000). It is associated with increased use of mental health services, 
especially for patients with signiﬁ  cant co-existing depressive symptoms who show 
a more severe and persistent course and greater functional impairment. Effective 
acute treatments include CBT, alprazolam, and benzodiazepines like diazepam and 
lorazepam, some SSRIs and serotonin and norepinephrine reuptake inhibitors (SN-
RIs), buspirone, the antipsychotic triﬂ  uorperazine and the antihistamine hydroxyzine 
(Baldwin et al 2005; Baldwin and Polkinghorn 2005). Psychological symptoms of 
anxiety may respond better to antidepressants than to benzodiazepines. Continuation 
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of CBT or an SSRI or SNRI for longer periods is associated 
with an increase in overall response and helps to prevent 
relapse (Baldwin et al 2005). 
There is a need for improvement in the treatment of GAD 
because the ideal anxiolytic drug does not exist, while CBT 
is not universally available especially in primary care where 
the majority of GAD patients ﬁ  rst present. In this issue, two 
views from either side of the Atlantic are presented on the 
potential role of pregabalin in the treatment of GAD (Bald-
win and Ajel 2007; Strawn and Geracioti 2007). Pregabalin 
is already approved in many countries for the treatment of 
chronic neuropathic pain and some forms of epilepsy. Its 
mechanism of action differs from that of known past treat-
ments for GAD – although structurally related to GABA, 
pregabalin neither binds to benzodiazepine, GABAA or 
GABAB receptors, nor affects GABA currents in the brain. 
It seems to bind to the α2δ sub-unit of brain voltage-gated 
N-type calcium channels, thereby decreasing presynaptic 
calcium currents and consequently lowering the release of a 
number of neurotransmitters which have been shown to be 
involved in the pathophysiology of GAD such as glutamate, 
substance P, and noradrenaline. 
The efﬁ  cacy of pregabalin in the acute treatment of GAD 
and prevention of relapse is well established in a series of 
randomized, placebo-controlled trials. When compared 
with existing treatments, it may offer an earlier onset of 
action than venlafaxine and better efﬁ  cacy across the range 
of psychological and somatic symptoms of anxiety than 
alprazolam or lorazepam. No speciﬁ  c antidepressant effects 
have yet been demonstrated and there is no study compar-
ing pregabalin with either CBT or a SSRI in GAD, which is 
problematical since most GAD patients in clinical settings 
have signiﬁ  cant co-existing depressive symptoms. The major 
side effects are dizziness and somnolence, while weight gain 
may be a problem, but in acute treatment studies pregabalin 
was generally better tolerated than benzodiazepines and 
venlafaxine. All-in-all, pregabalin is a promising newcomer 
for the treatment of GAD which may ultimately prove to 
be a viable alternative to current therapies. However, more 
(clinical) research is needed!
References
[APA] American Psychiatric Association. 2000. Diagnostic and Statistical 
Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR). 
Washington: APA, pp 472–6.
Aouizerate B, Guehl D, Cuny E, et al. 2005.Updated overview of the puta-
tive role of the serotoninergic system in obsessive-compulsive disorder. 
Neuropsychiatr Dis Treat, 1:231–43.
Baldwin DS, Ajel K. 2007. Role of pregabalin in the treatment of generalized 
anxiety disorder. Neuropsychiatr Dis Treat, 3:185–191.
Baldwin DS, Anderson IM, Nutt DJ, et al. 2005. Evidence-based guide-
lines for the pharmacological treatment of anxiety disorders: recom-
mendations from the British Association for Psychopharmacology. J 
Psychopharmacol, 19:567–96.
Baldwin DS, Polkinghorn C. 2005. Evidence-based pharmacotherapy of gen-
eralized anxiety disorder. Int J Neuropsychopharmacol, 8:293–302.
[CADTGI] Canadian Anxiety Disorders Treatment Guidelines Intiative. 
2007. Canad J Psychiatry, in press.
Greenberg P, Sisitsky T, Kessler R, et al. 1999. The economic burden of 
anxiety disorders in the 1990s. J Clin Psychiatry, 60:427–35.
Irons J. 2005. Fluvoxamine in the treatment of anxiety disorders. Neuro-
psychiatr Dis Treat, 1:289–99.
Katzman MA, Jacobs L. 2007. Venlafaxine in the treatment of panic dis-
order. Neuropsychiatr Dis Treat, 3:59–67.
Kessler R, McGonagle K, Zhao S, et al. 1994. Lifetime and 12-month 
prevalence of DSM-IIIR psychiatric disorders in the United States. 
Results from the national comorbidity survey. Arch Gen Psychiatry, 
51:8–19. 
Lewin AB, Storch EA, Geffken ER, et al. 2006. A neuropsychiatric review 
of pediatric obsessive-compulsive disorder: etiology and efﬁ  cacious 
treatments. Neuropsychiatr Dis Treat, 2:21–31.
Lieb R, Becker E, Altamura C. 2005. The epidemiology of generalized 
anxiety disorder in Europe. Eur Neuropsychopharmacol, 15:445–52.
Strawn JR, Geracioti TD. 2007. Pregabalin treatment of generalized anxiety 
disorder. Neuropsychiatr Dis Treat, 3:237–243. 